How Independent Adjudication Improves Consistency Across Sites and Clinical Outcomes

Independent adjudication uses a blinded Clinical Events Committee to review reported clinical events against predefined criteria, resolving site-to-site inconsistency in how events are classified. A documented charter, independent reviewers and a disagreement-reconciliation process make endpoint data consistent, reproducible and defensible to regulators.

Consistency is not a quality that a multicenter trial has naturally. It is something the trial has to build, and clinical adjudication is one of the mechanisms that builds it.

Two patients present with identical findings at two hospitals in two countries. One is recorded as a myocardial infarction, the other as a troponin rise of uncertain significance. Both investigators followed reasonable clinical practice. If both records enter the endpoint count as reported, the trial is measuring local documentation habits alongside the treatment effect.

The Problem: Inconsistent Event Assessment Across Sites

Divergence at site level comes from four sources, and none of them involves anyone doing their job badly.

Different diagnostic thresholds. Troponin assays differ, local cut-offs differ, and the decision to investigate differs with local resource and habit.

Different documentation practice. An event that is fully described in one discharge summary may appear as a single line in another, which changes what a reviewer can conclude from the record.

Different admission behavior. Endpoints defined by hospitalization inherit local admission thresholds. The same patient is admitted in one health system and sent home in another.

Knowledge of allocation. In an open-label study, an investigator who knows what the patient received cannot fully unknow it when deciding whether an ambiguous event qualifies.

The resulting inconsistency is not uniform across endpoint types. A 2023 methodological review in the European Heart Journal reported that agreement between site-reported and adjudicated events reached 98.1% for cardiovascular death in one trial, sat between roughly 70% and 90% for myocardial infarction, and fell to between 25% and 50% for unstable angina. In procedural settings, one committee identified 462 myocardial infarctions where investigators had reported 143.

How the Clinical Events Committee (CEC) Process Works

The adjudication workflow, step by step

The process is deliberately mechanical, because reproducibility is the point.

• Identification. Candidate events are flagged, not only from investigator reports but through a systematic search of the clinical database for findings that meet triggering criteria. A committee that only reviews what sites report inherits the sites' under-reporting.

• Document collection. The source documents required for that event type are requested, tracked and completed: discharge summaries, ECGs, laboratory results, imaging, procedure reports, autopsy findings.

• Redaction. Anything that could reveal treatment allocation is removed, including dispensation records, sponsor identifiers and laboratory values that could unblind by inference.

• Independent review. Each reviewer works alone, answering the same standardized set of questions in the same order, using an endpoint definition case report form rather than free judgment.

• Reconciliation. Where reviewers disagree, the predefined resolution path applies.

• Locking and export. The adjudicated classification is recorded with its supporting rationale and reconciled with the clinical database.

Every step is documented, and the documentation is the deliverable as much as the classification is.

Blinding and the adjudication charter

The charter is written before the first event is reviewed. It defines the endpoint definitions in operational terms, so that a reviewer is not interpreting a protocol sentence but applying a rule. It lists the documents required for each event type, sets the voting procedure, defines the reconciliation path, and establishes the committee's independence from the sponsor.

Blinding has to be operational rather than declared. A committee described as blinded that receives an unredacted discharge summary naming the study drug is not blinded. Redaction is an execution discipline, and it is where blinding usually fails in practice.

The same methodological review notes that adjudication is most likely to change a treatment effect estimate when investigators themselves were unblinded, a finding supported by a Cochrane review of 47 trials. Open-label designs are where a blinded committee does the most work.

Reconciling reviewer disagreement

Disagreement is expected. What matters is that its resolution was decided in advance rather than negotiated when it occurs.

Common structures include a third independent reviewer acting as tie-breaker, a full committee discussion producing a documented consensus, or a majority vote among at least three reviewers. The methodological literature recommends at least three committee members per event, independent voting, and standardized endpoint definition case report forms so that reviewers are answering identical questions.

The disagreement rate is itself useful information. A committee that never disagrees is probably not reviewing independently, and a committee that disagrees constantly is usually revealing that an endpoint definition is ambiguous and needs clarifying rather than that the reviewers are unreliable.

What Consistency Buys You

Four things, in descending order of visibility.

An endpoint that means one thing. The event count in the analysis reflects the protocol definition rather than the aggregate of local diagnostic habits.

Comparability across regions. Multi-regional trials are frequently asked to demonstrate consistency of effect across geographies. That question cannot be answered credibly if event classification varied by geography.

Statistical integrity. Misclassification in either direction distorts the event rate the study was powered on. Non-differential misclassification dilutes an effect; differential misclassification can create or hide one.

A traceable answer. When a reviewer asks why a specific event was counted, the answer is a documented decision linked to the source documents that supported it.

Adjudication vs Monitoring vs DSMB

These three are routinely confused, and the confusion has practical consequences when responsibilities are assigned.

The short version: monitoring checks transcription, adjudication decides classification, and a data safety monitoring board decides whether the trial should continue. Only the last one can stop a study.

Banook has been running adjudication committees since 2004, and began adjudicating major adverse cardiovascular events two years before FDA guidance addressed the subject. Committees draw on cardiologists, neurologists, radiologists and pneumologists, and the operational scope covers coordination and training of committee members, charter management, collection and tracking of medical records, quality control, archiving and audit-ready project documentation. Reviews run on a secure web portal supporting real-time centralization and multilingual consensus, which is what makes independent voting practical when a committee is distributed across several countries and working languages.

The case for adjudication, and the evidence on where it changes results, is covered in Why Endpoint Adjudication Remains Critical to Trial Credibility and Regulatory Confidence. You can also review the endpoint adjudication offering.

Frequently Asked Questions

How does a Clinical Events Committee work?

A CEC receives candidate events identified from investigator reports and from a systematic search of the clinical database. Source documents are collected and redacted to remove anything revealing treatment allocation. Each reviewer assesses the event independently using a standardized endpoint definition form. Disagreement is resolved through the path defined in the charter, and the final classification is recorded with its supporting rationale.

What is the adjudication process in clinical trials?

Adjudication is the structured review of reported clinical events against protocol definitions by independent, blinded experts. It runs in six stages: identification, document collection, redaction, independent review, reconciliation of disagreement, and locked export of the adjudicated classification.

How is disagreement between adjudicators resolved?

Through a mechanism defined in the charter before review begins. The usual options are a third independent reviewer acting as tie-breaker, a documented consensus discussion, or a majority vote among at least three reviewers. Persistent disagreement on one event type usually signals an ambiguous endpoint definition rather than unreliable reviewers.

CEC vs DSMB: what is the difference?

A clinical events committee classifies individual events against protocol definitions, stays blinded to treatment allocation, and has no authority over the conduct of the study. A data safety monitoring board reviews accumulating unblinded safety and efficacy data across the trial and can recommend stopping, pausing or modifying it.

Why does adjudication improve consistency?

Because it replaces many local judgments with one documented standard. Every event is assessed against the same operational definition, using the same required documents, answered through the same questions, by reviewers who cannot see what the patient received. Published data shows the gain is largest for endpoints that depend on interpretation, such as unstable angina or periprocedural myocardial infarction.